bivalirudin FDA Link

designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition

Also Known As:

Angiomax; Angiomax RTU; BG 8967; BG-8967; BG8967; CTB-001; Hirulog; Hirulog-1; L-leucine, D- phenylalanyl- L- prolyl- L- arginyl- L- prolylglycylglycylglycylglycyl- L- asparaginylglycyl- L- alpha- aspartyl- L- phenylalanyl- L- alpha- glutamyl- L- alpha- glutamyl- L- isoleucyl- L- prolyl- L- alpha- glutamyl- L- alpha- glutamyl- L- tyrosyl- ; Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen; Phe- Pro- Arg- Pro- (Gly)4- Asn- Gly- Asp- Phe- Glu- Glu- Ile- Pro- Glu- Glu- Tyr- Leu; Phe- Pro- Arg- Pro- (Gly)4- desulfohirudin- (53- 64); bivalirudin trifluoroacetate

Pharmalogical Action Categories:

D000991 - Antithrombins

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - bivalirudin: 1085
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        bivalirudin: 1085
- Peptides: 82426
  - Serpins: 906
    - Antithrombin Proteins: 6
      - Hirudins: 707
        bivalirudin: 1085
  - Peptide Fragments: 373
    - bivalirudin: 1085

David A Van De Car Selected Research

David A Van De Car Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure